Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

OBJECTIVE: Several trials have shown that pembrolizumab plus chemotherapy was more effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy monotherapy. However, whether pembrolizumab plus chemotherapy is still a better choice for first-line treatment in elderly patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyu, Chen, Ya, Wang, Yanan, Hu, Minjuan, Qian, Fangfei, Zhang, Yanwei, Zhang, Bo, Zhang, Wei, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882651/
https://www.ncbi.nlm.nih.gov/pubmed/35237263
http://dx.doi.org/10.3389/fimmu.2022.807575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882651/
https://www.ncbi.nlm.nih.gov/pubmed/35237263
http://dx.doi.org/10.3389/fimmu.2022.807575

Ejemplares similares